Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	Everolimus	1	72	flat	flat	BT20 everolimus 0 1 72	8	2.002	Inf	0.546	0.403	0.0	0.546	0.01	-0.000401	1.0	0.595	Inf	0.597	0.638	0.0	0.597	0.01	-0.327	1.0	0.636
Hs 578T	AZD-6482	3		sigmoid	sigmoid	Hs578T AZD6482 3	8	2.832	6.09	0.667	0.0547	24.1	-1.0	0.799	0.989	1.5e-06	NA	5.12	0.597	0.93	5.12	0.0	0.861	0.985	3.33e-06	NA
HCC70	WYE-125132	2	72	sigmoid	sigmoid	HCC70 WYE-132 0 2 72	8	1.675	0.213	0.471	0.332	0.0211	0.467	1.18	0.996	6.89e-08	NA	Inf	0.598	0.744	0.0194	0.595	1.17	0.996	7.52e-08	NA
BT-549	Sirolimus	1	72	sigmoid	sigmoid	BT549 rapamycin 0 1 72	8	1.817	3.62	0.51	0.438	0.000148	0.318	0.1	0.87	0.00218	NA	506850.0	0.6	0.638	8.82e-05	0.447	0.1	0.8	0.00802	NA
HCC38	Everolimus	2	72	sigmoid	flat	HCC38 everolimus 0 2 72	8	2.170	8323.0	0.58	0.376	0.000127	0.417	0.1	0.688	0.0303	NA	Inf	0.6	0.637	0.0	0.6	0.01	0.509	0.119	0.637
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6
BT-549	Everolimus	1	72	sigmoid	sigmoid	BT549 everolimus 0 1 72	8	1.772	5.64	0.503	0.444	1e-05	0.367	0.1	0.911	0.000706	NA	437200.0	0.603	0.641	0.000146	0.444	0.1	0.858	0.00286	NA
Hs 578T	Sirolimus	3		flat	flat	Hs578T rapamycin 3	8	2.836	Inf	0.675	0.309	0.0	0.675	0.01	-1.79	1.0	0.691	Inf	0.604	0.621	0.0	0.604	0.01	-3.02	1.0	0.621
BT-20	Trametinib	3	72	sigmoid	sigmoid	BT20 trametinib 0 3 72	8	2.539	Inf	0.64	0.208	0.104	0.541	0.392	0.967	3.69e-05	NA	Inf	0.604	0.761	0.0656	0.513	0.391	0.964	4.56e-05	NA
HCC70	Trametinib	2	72	sigmoid	sigmoid	HCC70 trametinib 0 2 72	8	1.721	0.506	0.504	0.395	0.00469	0.467	0.581	0.944	0.000179	NA	Inf	0.612	0.687	0.00389	0.585	0.57	0.948	0.000138	NA
HCC38	Sirolimus	2	72	flat	flat	HCC38 rapamycin 0 2 72	8	2.106	Inf	0.588	0.371	0.0	0.588	0.01	0.496	0.128	0.629	Inf	0.616	0.65	0.0	0.616	0.01	0.246	0.429	0.649
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.0	0.627	0.01	-1.01	1.0	0.649
Hs 578T	Sirolimus	1		sigmoid	sigmoid	Hs578T rapamycin 1	8	2.013	110643.0	0.587	0.358	0.000237	0.432	0.1	0.879	0.00178	NA	9.61e+11	0.628	0.672	0.000175	0.487	0.1	0.851	0.00332	NA
Hs 578T	MK2206	2		sigmoid	sigmoid	Hs578T MK-2206 2	8	2.530	Inf	0.664	0.131	0.0699	0.752	1.34	0.75	0.0156	NA	Inf	0.628	0.848	0.0616	0.717	1.21	0.767	0.0126	NA
HCC38	Sirolimus	1	72	flat	flat	HCC38 rapamycin 0 1 72	8	1.723	Inf	0.531	0.429	0.0	0.531	0.01	0.623	0.0538	0.573	Inf	0.631	0.66	0.0	0.631	0.01	0.536	0.0998	0.661
Hs 578T	Alpelisib	2		flat	flat	Hs578T alpelisib 2	8	2.513	Inf	0.668	0.131	0.0	0.668	0.01	0.599	0.0647	0.856	Inf	0.634	0.847	0.0	0.634	0.01	0.541	0.0969	0.833
HCC38	Everolimus	1	72	sigmoid	flat	HCC38 everolimus 0 1 72	8	1.703	11.8	0.54	0.428	0.000126	0.341	0.1	0.688	0.0303	NA	Inf	0.641	0.664	0.0	0.641	0.01	0.571	0.0788	0.665
Hs 578T	Alpelisib	3		sigmoid	sigmoid	Hs578T alpelisib 3	8	2.856	Inf	0.712	0.0759	0.872	0.616	0.828	0.963	5.21e-05	NA	Inf	0.641	0.901	0.65	0.553	0.853	0.955	8.85e-05	NA
Hs 578T	MK2206	1		sigmoid	sigmoid	Hs578T MK-2206 1	8	2.039	Inf	0.608	0.165	0.087	0.665	2.09	0.9	0.00101	NA	Inf	0.641	0.845	0.0803	0.689	1.9	0.908	0.000775	NA
HCC38	Pictilisib	2	72	sigmoid	sigmoid	HCC38 pictilisib 0 2 72	8	2.112	Inf	0.622	0.0838	0.644	0.58	1.32	0.933	0.000298	NA	Inf	0.642	0.918	0.568	0.612	1.36	0.922	0.000475	NA
BT-549	Sirolimus	2	72	flat	flat	BT549 rapamycin 0 2 72	8	1.830	Inf	0.569	0.384	0.0	0.569	0.01	0.517	0.113	0.618	Inf	0.642	0.677	0.0	0.642	0.01	0.465	0.153	0.679
BT-549	Trametinib	3	72	sigmoid	sigmoid	BT549 trametinib 0 3 72	8	1.755	Inf	0.553	0.223	0.107	0.505	0.899	0.942	0.000194	NA	Inf	0.642	0.817	0.104	0.595	0.804	0.938	0.000236	NA
HCC70	AS605240	2	72	sigmoid	sigmoid	HCC70 AS-605240 0 2 72	8	1.771	6.13	0.558	0.126	1.21	0.339	0.698	0.981	7.24e-06	NA	785.0	0.643	0.894	0.946	0.496	0.708	0.978	1.04e-05	NA
HCC38	Pictilisib	1	72	sigmoid	sigmoid	HCC38 pictilisib 0 1 72	8	1.759	7.16	0.562	0.125	1.04	0.377	0.725	0.992	5.12e-07	NA	Inf	0.647	0.896	0.797	0.529	0.742	0.992	5.77e-07	NA
HCC38	AS605240	2	72	sigmoid	sigmoid	HCC38 AS-605240 0 2 72	8	2.200	17.4	0.642	0.114	4.07	0.256	0.493	0.936	0.000265	NA	46.2	0.648	0.882	1.68	0.411	0.522	0.929	0.000356	NA

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)